BioDefense Portfolio

In addition to BioThrax® (Anthrax Vaccine Adsorbed), our biodefense product portfolio includes three biodefense product candidates in preclinical development and a next generation anthrax vaccine program with product candidates in preclinical and Phase I clinical development. We are developing all of our biodefense product candidates to address category A biological agents, which are the class of biological agents that the CDC has identified as the greatest possible threat to public health. Our biodefense product candidates in preclinical development are:

• Anthrax Immune Globulin – for post-exposure treatment of anthrax infection, which we are developing in part with funding from NIAID.
• Recombinant Bivalent Botulinum Vaccine – a prophylaxis for illness caused by botulinum toxin, which we also are developing in collaboration with HPA
• Botulinum Immune Globulin – for post-exposure treatment of illness caused by botulinum toxin, which we are developing based on a new botulinum toxoid vaccine that we are developing in collaboration with the U.K. Health Protection Agency, or HPA

In addition, we are evaluating several potential product candidates in connection with development of a next generation anthrax vaccine, featuring attributes such as self administration and a longer shelf life.

ALL INVESTIGATIONAL PRODUCTS MUST SUCCESSFULLY COMPLETE THEIR RESPECTIVE DEVELOPMENT PROGRAMS AND BE APPROVED BY THE FDA (AND/OR FOREIGN EQUIVALENTS) BEFORE THEY MAY BE MARKETED.